

# **Global Neuroendocrine Tumours Therapeutics Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023**

<https://marketpublishers.com/r/G205267AEDDEN.html>

Date: November 2017

Pages: 218

Price: US\$ 4,400.00 (Single User License)

ID: G205267AEDDEN

## **Abstracts**

### **Global Neuroendocrine Tumours Therapeutics Market**

Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body. Most neuroendocrine tumours occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arise from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.

Neuroendocrine tumours therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumours are expected to drive the growth of the market. AACR provided \$250,000 fund for the Prevention of neuro endocrine tumours. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumours in developing regions is anticipated to drive global neuroendocrine tumours market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumours market.

The global neuroendocrine tumours therapeutics market is segmented on the basis of the indication, distribution channel, drug class, and geographical regions.

Based on indication, global neuroendocrine tumours therapeutics market is segmented as

Lung NET

Others NET

Gastrointestinal NET

Pancreatic NET

Based on distribution channel, global neuroendocrine tumour treatment market is segmented as:

Hospital Pharmacies

Retail Pharmacies

Others

Based on therapy, global neuroendocrine tumour treatment Market is segmented as

Surgery

Chemotherapy

Radiation Therapy

The neuroendocrine tumour treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival

rate of neuroendocrine tumours by treating with various medications are expected to have a positive impact on neuroendocrine tumours market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.

Based on the geographical regions, global neuroendocrine tumours market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumours therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America's neuroendocrine tumours therapeutics market. Europe is the second largest market for neuroendocrine tumours therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Some of the players operating in the global neuroendocrine tumours therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).

In 2016, Novartis received the U.S. FDA approval for its Afinitor®(everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin

In 2014, Ipsen Biopharmaceuticals, Inc., received U.S.FDA approval for Somatuline®Depot® (lanreotide) Injection 120 mg to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients

#### Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key

findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET INTRODUCTION**

2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy

2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions

2.2.1. Drug Class

2.2.2. Indication

2.2.3. Distribution Channel

### **3. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis

3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations

### **4. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023**

5.1. Somatostatin Analogues

#### 5.1.1. Octreotide

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

#### 5.1.2. Lanreotide

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

#### 5.1.3. Pasireotide

5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

### 5.2. Chemotherapeutics

#### 5.2.1. Fluorouracil (5-FU)

5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.1.3. Market Opportunity Analysis

#### 5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.2.3. Market Opportunity Analysis

#### 5.2.3. Streptozocin

5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.3. Market Opportunity Analysis

#### 5.2.4. Capecitabine (Xeloda)

5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.4.3. Market Opportunity Analysis

#### 5.2.5. Dacarbazine (DTIC)

5.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

- 5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 5.2.5.3. Market Opportunity Analysis
- 5.2.6. Temozolomide (Temodar)
  - 5.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  - 5.2.6.3. Market Opportunity Analysis
- 5.2.7. Oxaliplatin (Eloxatin)
  - 5.2.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  - 5.2.7.3. Market Opportunity Analysis
- 5.3. Targeted Therapeutics
  - 5.3.1. Sunitinib
    - 5.3.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    - 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    - 5.3.1.3. Market Opportunity Analysis
  - 5.3.2. Everolimus
    - 5.3.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    - 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
    - 5.3.2.3. Market Opportunity Analysis
- 5.4. Others
  - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  - 5.4.3. Market Opportunity Analysis

## **6. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 6.1. Lung NET
  - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  - 6.1.3. Market Opportunity Analysis
- 6.2. Gastrointestinal NET
  - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  - 6.2.3. Market Opportunity Analysis

### 6.3. Pancreatic NET

- 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.3.3. Market Opportunity Analysis

### 6.4. Others

- 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.4.3. Market Opportunity Analysis

## **7. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 7.1. Retail Pharmacies

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.1.3. Market Opportunity Analysis

### 7.2. Hospital Pharmacies

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.2.3. Market Opportunity Analysis

### 7.3. Others

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.3.3. Market Opportunity Analysis

## **8. GLOBAL NEUROENDOCRINE TUMORS THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis

### 8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.2.3. Market Opportunity Analysis

### 8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis



### 8.3.3. Market Opportunity Analysis

## 8.4. Latin America

### 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

### 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

### 8.4.3. Market Opportunity Analysis

## 8.5. Middle East and Africa

### 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

### 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

### 8.5.3. Market Opportunity Analysis

## 8.6. Global Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2017 – 2023

# **9. NORTH AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

## 9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

### 9.1.1.1. Somatostatin Analogues

#### 9.1.1.1.1. Octreotide

#### 9.1.1.1.2. Lanreotide

#### 9.1.1.1.3. Pasireotide

### 9.1.1.2. Chemotherapeutics

#### 9.1.1.2.1. Fluorouracil (5-FU)

#### 9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

#### 9.1.1.2.3. Streptozocin

#### 9.1.1.2.4. Temozolomide (Temodar)

#### 9.1.1.2.5. Capecitabine (Xeloda)

#### 9.1.1.2.6. Dacarbazine (DTIC)

#### 9.1.1.2.7. Oxaliplatin (Eloxatin)

### 9.1.1.3. Targeted Therapeutics

#### 9.1.1.3.1. Sunitinib

#### 9.1.1.3.2. Everolimus

### 9.1.1.4. Others

## 9.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

### 9.1.2.1. Lung NET

### 9.1.2.2. Others NET

### 9.1.2.3. Gastrointestinal NET

### 9.1.2.4. Pancreatic NET

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Retail Pharmacies

9.1.3.2. Hospital Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2017 – 2023

9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

## **10. EUROPE NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Somatostatin Analogues

10.1.1.1.1. Octreotide

10.1.1.1.2. Lanreotide

10.1.1.1.3. Pasireotide

10.1.1.2. Chemotherapeutics

10.1.1.2.1. Fluorouracil (5-FU)

10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

10.1.1.2.3. Streptozocin

10.1.1.2.4. Temozolomide (Temodar)

10.1.1.2.5. Capecitabine (Xeloda)

10.1.1.2.6. Dacarbazine (DTIC)

10.1.1.2.7. Oxaliplatin (Eloxatin)

10.1.1.3. Targeted Therapeutics

10.1.1.3.1. Sunitinib

10.1.1.3.2. Everolimus

10.1.1.4. Others

10.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Lung NET

10.1.2.2. Others NET

10.1.2.3. Gastrointestinal NET

10.1.2.4. Pancreatic NET

10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Retail Pharmacies

10.1.3.2. Hospital Pharmacies

10.1.3.3. Others

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023

10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

## **11. ASIA-PACIFIC NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Somatostatin Analogues

11.1.1.1.1. Octreotide

11.1.1.1.2. Lanreotide

11.1.1.1.3. Pasireotide

11.1.1.2. Chemotherapeutics

11.1.1.2.1. Fluorouracil (5-FU)

11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

11.1.1.2.3. Streptozocin

11.1.1.2.4. Temozolomide (Temodar)

11.1.1.2.5. Capecitabine (Xeloda)

11.1.1.2.6. Dacarbazine (DTIC)

11.1.1.2.7. Oxaliplatin (Eloxatin)

#### 11.1.1.3. Targeted Therapeutics

##### 11.1.1.3.1. Sunitinib

##### 11.1.1.3.2. Everolimus

##### 11.1.1.4. Others

#### 11.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

##### 11.1.2.1. Lung NET

##### 11.1.2.2. Others NET

##### 11.1.2.3. Gastrointestinal NET

##### 11.1.2.4. Pancreatic NET

#### 11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

##### 11.1.3.1. Retail Pharmacies

##### 11.1.3.2. Hospital Pharmacies

##### 11.1.3.3. Others

#### 11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

##### 11.1.4.1. Japan

##### 11.1.4.2. China

##### 11.1.4.3. India

##### 11.1.4.4. ASEAN

##### 11.1.4.5. Australia & New Zealand

##### 11.1.4.6. Rest of Asia-Pacific

#### 11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023

#### 11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

## **12. LATIN AMERICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

##### 12.1.1.1. Somatostatin Analogues

###### 12.1.1.1.1. Octreotide

###### 12.1.1.1.2. Lanreotide

###### 12.1.1.1.3. Pasireotide

##### 12.1.1.2. Chemotherapeutics

- 12.1.1.2.1. Fluorouracil (5-FU)
- 12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
- 12.1.1.2.3. Streptozocin
- 12.1.1.2.4. Temozolomide (Temodar)
- 12.1.1.2.5. Capecitabine (Xeloda)
- 12.1.1.2.6. Dacarbazine (DTIC)
- 12.1.1.2.7. Oxaliplatin (Eloxatin)
- 12.1.1.3. Targeted Therapeutics
  - 12.1.1.3.1. Sunitinib
  - 12.1.1.3.2. Everolimus
- 12.1.1.4. Others
- 12.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.1.2.1. Lung NET
  - 12.1.2.2. Others NET
  - 12.1.2.3. Gastrointestinal NET
  - 12.1.2.4. Pancreatic NET
- 12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.1.3.1. Retail Pharmacies
  - 12.1.3.2. Hospital Pharmacies
  - 12.1.3.3. Others
- 12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 12.1.4.1. Brazil
  - 12.1.4.2. Mexico
  - 12.1.4.3. Argentina
  - 12.1.4.4. Venezuela
  - 12.1.4.5. Rest of Latin America
- 12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023
- 12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

### **13. MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Somatostatin Analogues

13.1.1.1.1. Octreotide

13.1.1.1.2. Lanreotide

13.1.1.1.3. Pasireotide

13.1.1.2. Chemotherapeutics

13.1.1.2.1. Fluorouracil (5-FU)

13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

13.1.1.2.3. Streptozocin

13.1.1.2.4. Temozolomide (Temodar)

13.1.1.2.5. Capecitabine (Xeloda)

13.1.1.2.6. Dacarbazine (DTIC)

13.1.1.2.7. Oxaliplatin (Eloxatin)

13.1.1.3. Targeted Therapeutics

13.1.1.3.1. Sunitinib

13.1.1.3.2. Everolimus

13.1.1.4. Others

13.1.2. Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Lung NET

13.1.2.2. Others NET

13.1.2.3. Gastrointestinal NET

13.1.2.4. Pancreatic NET

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Retail Pharmacies

13.1.3.2. Hospital Pharmacies

13.1.3.3. Others

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Neuroendocrine Tumors Therapeutics Market - Opportunity Analysis Index By Drug Analysis, Indication, Distribution Channel and Country, 2017 – 2023

13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

## 14. COMPETITION LANDSCAPE

#### 14.1. Strategic Dashboard of Top Market Players

#### 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Pfizer Inc., (U.S)

14.2.2. Eli Lilly & Company (U.S.)

14.2.3. Novartis AG (Switzerland)

14.2.4. F. Hoffmann-La Roche Ltd.(Switzerland)

14.2.5. Ipsen (France)

14.2.6. Amgen, Inc. (U.S.)

14.2.7. Teva Pharmaceuticals, Ltd. (Israel)

14.2.8. Bristol-Myers Squibb (U.S.)

### **15. RESEARCH METHODOLOGY**

### **16. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Global Neuroendocrine Tumours Therapeutics Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G205267AEDDEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G205267AEDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



